Wilson Sonsini Goodrich & Rosati advised Denali Therapeutics on the deal, while Davis Polk advised the representatives of the several underwriters. Denali Therapeutics, a biopharmaceutical company...
Denali Therapeutics’ $316 Million Public Offering
Cantor Fitzgerald and Howard Lutnick’s $400 Million Stockholder Derivative Suit
Latham successfully represented Cantor Fitzgerald, L.P., CF Group Management Inc. (together with Cantor Fitzgerald, L.P., Cantor), and Howard Lutnick in the lawsuit. On August 19, 2022,...
Village Farms International’s $50 Million Equity Offering Sales Agreement
Miller Thomson acted as Canadian counsel to the Sales Agents. Village Farms International, Inc. (NASDAQ:VFF) announced that it has entered into a Controlled Equity Offering Sales Agreement...
Cytokinetics’ $540 Million Convertible Senior Notes Offering
Latham & Watkins represented the initial purchasers in the offering while Cooley advised Cytokinetics. Cytokinetics, Incorporated, a late-stage biopharmaceutical company, has announced the pricing of its...
Chinook Therapeutics’ $105 Million Public Offering
Latham & Watkins represented the underwriters in the offering. Chinook Therapeutics, Inc. (Nasdaq: KDNY) has announced the pricing of its underwritten public offering of 6,428,572 shares...
Denali Therapeutics’ $400 Million At-The-Market Offering
Davis Polk advised the sales agents in the transaction. The transaction consists in a new SEC-registered at-the-market offering program by Denali Therapeutics Inc. under which Denali...
Vaxcyte’s $100 Million Shares Offering
Latham & Watkins represented the underwriters in the transaction. Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of...
Brigade-M3 European Acquisition’s $250 Million Initial Public Offering
Latham & Watkins, Stibbe and Maples and Calder advised Brigade-M3 European Acquisition Corp on the deal. Linklaters advised Cantor Aurel and Cantor Fitzgerald Europe. Brigade-M3 European...
Blade Therapeutics’ Merger With Biotech Acquisition Company
Latham& Watkins advised Blade, Ellenoff Grossman & Schole advised BAC, and Simpson Thacher & Bartlett advised Barclays and Cantor in their role as placement agents for...
Cardiol Therapeutics’ $50 Million Public Offering
Torys LLP acted as Canadian counsel to the underwriters. On November 5, 2021, Cardiol Therapeutics Inc. closed its previously announced public offering of 16,350,000 units at a...
Alpha Tau’s Business Combination with Healthcare Capital Corp.
Latham & Watkins LLP represented Alpha Tau in the transaction, while Winston & Strawn represented the placement agent. Alpha Tau Medical Limited, the developer of the...
Phreesia’s $245.3 Million Common Stock Offering
Latham & Watkins LLP represented the underwriters in the offering. Phreesia, Inc., a leading patient intake management platform, has announced the closing of the underwritten public...